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ower Homocysteine Levels in Renal Transplant Recipients
reated With Everolimus: A Possible Link With A Decreased
ardiovascular Risk?
. Farsetti, M. Zanazzi, L. Caroti, G. Rosso, A. Larti, R. Marcucci, S. Fedi, A. Rogolino, A.P. Cellai,
. Abbate, E. Bertoni, and M. Salvadori
ABSTRACT
Cardiovascular disease (CVD) is the main cause of morbidity and mortality in renal
transplant recipients. The incidence of CVD in this setting is approximately 5-fold greater
than in age- and and gender-matched subjects. This excess cardiovascular risk is not
completely explained by traditional cardiac risk factors. It has been well documented that
these patients show greatly increased prevalence of both fasting and postmethionine-
loading hyperhomocysteinemia (hHcy) compared with the general population. An immu-
nosuppressive therapy based on everolimus has been demonstrated to reduce the
incidence major adverse coronary events at 4 years compared with azathioprine among
heart transplant recipients. In contrast, scarce data are available on the impact of
everolimus on emerging risk factors, such as homocysteine (Hcy), in renal transplant
recipients. The aim of this study was to evaluate the possibile impact of everolimus
compared with other immunosuppressive regimes among 132 stable recipients, including
91 men and 41 women who were at least 1 year after transplant with stable renal function
and no clinical evidence of acute or chronic renal graft rejections. We compared 31
subjects on everolimus immunosuppressive therapy (group A) versus 101 on immunosup-
pressive therapy based on cyclosporine, steroids, and mycophenolate. The Hcy levels were
significantly lower among group A patients compared with group B: 16.5  5 mol/L vs
21.2  11 mol/L; P  .005. Hyper-Hcy, defined as Hcy levels 15 mol/L, was diagnosed
in 18 out of 31 patients (51%) of group A and in 82 out of 101 patients (81%) of group B.
This preliminary study demonstrates a favorable impact of everolimus on a marker of












ardiovascular disease (CVD) is the main cause of
morbidity and mortality in renal transplant recipients
RTRs).1 Indeed, the incidence of CVD in RTRs is approx-
mately 5-fold greater than in age- and and gender-7
atched subjects. This excess cardiovascular risk is not
ompletely explained by the number of traditional cardiac
isk factors to which RTRs are exposed. The greatly in-
reased prevalence of both fasting and postmethionine
oading hyperhomocysteinemia (hHcy) in RTRs compared
ith the general population has been well documented.2–4
n immunosuppressive therapy based on everolimus has
een demonstrated to reduce the incidence of 4-year major
dverse coronary events compared with azathioprine in
eart transplantation.5 On the other hand, no data are
vailable on the impact of everolimus on emerging risk 5
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ransplantation Proceedings, 42, 1381–1382 (2010)actors, such as Hcy, in RTRs. The aim of the present study
as to evaluate the possible impact of everolimus compared
ith other immunosuppressive regimes on Hcy levels.
ATIENTS AND METHODS
e investigated 229 stable RTRs (150 male, 79 female) at least 1
ear after transplant with stable renal function and no clinical
vidence of acute or chronic renal graft rejection episodes. Thirty-
ine RTRs were on immunosuppressive therapy based on everoli-
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1382 FARSETTI, ZANAZZI, CAROTI ET ALus (group A), and 190 were on immunosuppressive therapy based
n triple therapy (cyclosporine, steroids, micophenolate; group B).
Statistical analysis was performed by means of the SPSS package.
ata are reported as mean  SD. The comparison between
ifferent groups was performed by a Mann-Whitney U test. All
robability values were 2 tailed, with values of .05 considered to
e statistically significant.
ESULTS
o significant differences were documented between the 2
roups in the dialysis age, graft duration, or creatinine
evels. Hcy levels were significantly lower in patients of
roup A compared with group B: 16.5  5 mol/L vs 21.2 
1 mol/L; P  .005. Hyper-Hcy, defined as hHcy levels
15 mol/L, was diagnosed in 23 out of 39 patients (58.9%)
f group A and in 144 out of 190 patients (75.8%) of group B.
o significant differences were found in vitamin B6 levels:
.0  3.5 gram/L vs 4.4  3.4 gram/L.
ISCUSSION
everal studies have found increased levels of Hcy both in
atients with end-stage renal disease and in RTRs with a
ecovered renal function.2–4 We previously demonstrated,
n the same clinical setting of the present study, that vitamin
upplementation reduces the carotid artery intima-media
hickness in renal transplant recipients with hHcy.6 In the
resent paper, we confirmed the high prevalence of mild
Hcy in RTRs. Notably, this preliminary study demon-
trates a favorable impact of everolimus on this marker of
therothrombosis which is associated with a worse vascular
rognosis. The proliferation-signal inhibitor (PSI)/mamma-
ian target of rapamycin (mTOR) inhibitors sirolimus and
verolimus have shown considerable promise in reducing
cute rejection episodes in renal transplant recipients.
lthough PSIs are associated with an increase in hyperlip-
demia, which is a major risk factor for atherosclerosis and
ssociated cardiovascular disease, recent studies with siroli-
us have demonstrated protection from atheroma progres-
ion in hyperlipidemic apolipoprotein E–deficient mice.
irolimus and everolimus inhibit the mTOR signaling path-
ay, inducing inhibition of gene transcription, reduced cell
rowth and proliferation, reduced vascular endothelial
t
t
rowth factor production. In the endothelial cell, the effect
f PSIs is reduced cell growth and proliferation. Further-
ore, there may also be alterations in endothelial nitric
xide synthase expression, changes in the ratio of matrix
etalloproteinases (MMP) to tissue inhibitors of metallo-
roteinases, MMP-2 and MMP-9 activation, reduced expres-
ion of the positive cell-cycle regulator cyclin-dependent
inase 2, proliferating-cell nuclear antigen, and proinflam-
atory cytokines, and diminished expression of monocyte
hemotactic protein 1, which is associated with the attenu-
tion of monocyte chemotaxis and reduced neointimal
acrophage counts in sirolimus-fed mice.
The potential protective role of mTOR inhibitors, par-
icularly everolimus, in the processes that lead to athero-
clerosis and cardiovascular events seems to be confirmed
y the results of this preliminary study. Hcy levels, which
epresent an independent risk factor for cardiovascular
isease, are significantly reduced in renal transplant pa-
ients treated with everolimus compared with patients
reated with other immunosuppressive regimens. Larger
rospective studies are needed to clarify the impact that the
se of everolimus may have on methionine metabolism and
n morbidity and mortality from cardiovascular causes in
TRs.
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